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Abstract
Sirt1, an NAD-dependent protein deacetylase has emerged as important regulator of mammalian
transcription in response to cellular metabolic status and stress1. Here we demonstrate that Sirt1
plays a neuroprotective role in models of Huntington’s disease (HD), an inherited
neurodegenerative disorder caused by a glutamine repeat expansion in huntingtin protein2. Brain-
specific knockout of Sirt1 results in exacerbation of brain pathology in HD mice, whereas
overexpression of Sirt1 improves survival, neuropathology and BDNF expression in HD mice. We
show that Sirt1 deacetylase activity directly targets neurons to mediate neuroprotection from
mutant huntingtin. The neuroprotective effect of Sirt1 requires the presence of TORC1, a brain-
specific modulator of CREB activity3. We show that under normal conditions Sirt1 deacetylates
and activates TORC1 by promoting its dephoshorylation and interaction with CREB. We
identified BDNF as an important target of Sirt1 and TORC1 transcriptional activity in normal and
HD neurons. Mutant huntingtin interferes with the TORC1-CREB interaction to repress BDNF
transcription and Sirt1 rescues this defect in vitro and in vivo. These studies suggest a key role of
Sirt1 in transcriptional networks in normal and HD brain and offer an opportunity for therapeutic
development.
Recent evidence suggests that Sirt1, a member of sirtuin family that has been implicated in
aging and metabolism, plays a protective role in neurodegenerative disorders1. However, the
exact nature of normal Sirt1 function in mammalian brain has yet to be ascertained. To
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tclarify the function of Sirt1 in brain and determine its contribution to neurodegeneration, we
focused on Huntington’s disease (HD), an autosomal dominant disease that commonly
presents in adult life with personality changes, cognitive changes, psychiatric disturbances
and abnormal movements2. HD belongs to a family of polyglutamine disorders that, in
addition to expanded polyglutamine repeats, share other features such as adult onset,
progressive neurodegeneration, inverse correlation of numbers of repeats with age of onset
and presence of polyglutamine protein-containing inclusions 2. Polyglutamine diseases,
including HD remain fatal as there are no effective treatments to cure the diseases or to slow
their progression.
The role of Sirt1 in HD has been primarily studied in Drosophila melanogaster and in C.
elegans, but the results have been contradictory. For example, in worms overexpressing Sir2
(ortholog of human Sirt1), HTT-induced neurodegeneration is suppressed, whereas
overexpression in fly model of HD confers no significant protection 4,5. To begin testing the
role of Sirt1 in HD mice, we first crossed a conditional allele of Sirt1 (Sirt1flox) to the
Nestin-cre driver to yield Sirt1 brain-specific knockout mice (BSKO, genotype Sirt1flox/flox;
nestin-cre). These mice were born at mendelian ratios and displayed no gross defects in
brain development 6. To determine the impact of the ablation of neuronal Sirt1 on HD, we
then crossed BSKO mice to the R6/2 model of HD 7. These crosses, which were carried out
on an inbred C57BL/6 background, yielded Sirt1flox/flox controls (referred to as WT),
Sirt1flox/flox; R6/2 (R6/2), Sirt1flox/flox; nestin-cre (BSKO), and Sirt1flox/flox; nestin-cre-R6/2
(BSKO-R6/2). Behavioral experiments revealed significant acceleration of motor deficits in
BSKO-R6/2 compared to R6/2 mice as assessed by rotarod performance (Figs. 1a and
Supplementary Fig. 1a). To determine if neuropathological alterations accompanied the
behavioral phenotype, an unbiased stereological analysis of brain sections was performed.
Previous studies have demonstrated that R6/2 mice exhibit progressive atrophy of striatal
neurons that resembles neuropathology observed in human HD 8. As expected, R6/2 mice
showed significant striatal atrophy compared to WT mice (Fig. 1b). BSKO mice, which are
smaller than WT mice 6, also had smaller striata than the WT mice. BSKO-R6/2 mice
showed significantly smaller striatal volume compared to BSKO or R6/2 mice (Fig. 1c).
Moreover, when analyzing a series of sections spanning the striatum, a significant decrease
in the mean neuronal volume was observed in striata of the BSKO-R6/2 mice compared to
R6/2 mice (Fig. 1c). To examine aggregation of mutant HTT, mean aggregate count was
examined in all four genotypes. While no HTT aggregates were observed in WT or BSKO
mice, the number of aggregates was significantly increased in BSKO-R6/2 animals as
compared to R6/2 mice (Fig. 1d). These results demonstrate that deficiency of Sirt1
accelerates neurodegeneration in HD mice.
To test whether increased expression of Sirt1 might provide protection in the R6/2 model of
HD, we took advantage of a transgenic mouse that over-expresses Sirt1 under the control of
the endogenous β-actin promoter (Sirt1-KI) 9. These mice, which are maintained on an
outbred genetic background, over-express Sirt1 in a variety of tissues, including the brain
where Sirt1 is over-expressed approximately two-fold in both cortex and striatum, but the
over-expression was less pronounced in female Sirt1-KI mice (Supplementary Fig. 1b,c).
We crossed Sirt1 over-expressing mice (genotype Sirt1- KI/+) to R6/2 mice to generate
wild-type (WT), Sirt1-KI, unmodified R6/2 and Sirt1 over-expressing R6/2 (Sirt1-KI-R6/2).
These four groups were born at the expected mendelian ratios. Analysis of body weight loss
and rotarod performance revealed that Sirt1 over-expression was unable to provide
significant protection against these two gross phenotypes in the R6/2 mouse (Supplementary
Fig. 1d,e). However, we found that Sirt1 over-expression significantly extended the survival
of R6/2 animals, from an average of 100 d to an average of 130 d (Fig. 1e). Interestingly,
this effect was observed only in male mice, whereas female mice showed no differences in
survival (Supplementary Fig. 1f). Although the precise reasons for this gender-specific
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teffect remain unclear, it is possible that lower levels of Sirt1 overexpression in female Sirt1-
KI mice played a role (Supplementary Fig. 1c). Intriguingly, Sirt1 over-expression did not
extend the lifespan of otherwise normal mice (Supplementary Fig. 2), indicating that the
lifespan extension provided by this strain is specific to the pathology of HD.
Neuropathological analysis revealed significant striatal and neuronal atrophy in R6/2 mice
as compared to either WT or SIRT1-KI animals (Fig. 1f,g). However, the degree of both
striatal and neuronal atrophy was significantly reduced in SIRT1-KI-R6/2 mice as compared
to R6/2, indicating that over-expression of Sirt1 protected against striatal degeneration in
this model (Fig. 1f,g). Further, an analysis of protein aggregate formation revealed that
Sirt1-KI-R6/2 animals had a significantly reduced aggregate burden as compared to R6/2
animals (Figs. 1h and Supplementary Fig. 3). These results indicate that Sirt1 over-
expression can provide significant protection against key neuropathological phenotypes in
the HD mouse model.
Having shown that overexpression of Sirt1 protects from mutant HTT toxicity in vivo, we
asked whether this protection was due to direct effects of Sirt1 on neurons. Using lentiviral
expression in primary neurons we achieved high transduction efficiency (> 90%) and
predominantly neuronal expression of the transduced constructs (Supplementary Fig. 4a).
Neurofilament staining (NF) was utilized to detect degeneration of neurites as an early
marker of neuronal toxicity10. These experiments revealed progressive loss of NF staining
that correlated with the duration of exposure of primary neurons to mutant HTT
(Supplementary Fig. 4b). Lentiviral expression of mutant HTT with 72Qs resulted in
significant loss of neurites compared to wild-type HTT with non-expanded polyQ tract (Fig.
2a,b). Expression of lenti-Sirt1 significantly rescued neuronal toxicity of mutant HTT
despite the fact that only about 70% of neurons coexpressed both Sirt and mutant HTT (Fig.
2a,b). This protection is mediated by deacetylase activity of Sirt1 since deacetylase-deficient
Sirt1 H363Y (Sirt1 HY) did not exhibit significant neuroprotection compared with wild-type
Sirt1 (Fig. 2b). Using nuclear staining as readout, we found that Sirt1 also protected from
mutant HTT-induced nuclear toxicity that invariably followed loss of NF staining
(Supplementary Fig. 4b,c). These experiments demonstrate that Sirt1 directly protects
neurons from mutant HTT toxicity and that Sirt1 deacetylase activity plays a key role in the
neuroprotection.
To examine the mechanism of Sirt1-mediated neuroprotection in HD mice, we first
performed gene expression profiling in striatal samples obtained from HD mice and HD
mice crossed with Sirt1 overexpressing mice. Gene Set Enrichment Analysis11 revealed that
overexpresion of Sirt1 in HD mice rescued specific pathways involved in neurite
development and branching (Supplementary Fig. 5). In addition, BDNF, an important
regulator of these pathways12,13, was significantly decreased in HD mice as previously
described 14, whereas BDNF levels were significantly higher in HD-Sirt1-KI mice compared
to HD mice (Fig. 2c). By contrast, cortical brain samples from Sirt1 BSKO mice showed
significantly decreased levels of BDNF mRNA compared to control littermates (Fig. 2d),
further suggesting that Sirt1 might regulate BDNF expression. Importantly, experiments in
primary cortical neurons isolated from the Sirt1 KO mice revealed that treatment with
exogenous BDNF rescued neurotoxicity observed in the KO cultures (Fig. 2e). Taken
together, these results highlight BDNF as an important target of Sirt1 function in normal and
HD brain and suggest that Sirt1 regulates expression of BDNF at the level of transcription.
Previous studies in primary neurons demonstrated that CREB-mediated transcription from
BDNF promoter IV (previous nomenclature III) accounts for most BDNF gene expression
under conditions of neuronal activity 15. Co-transfection experiments revealed significant
activation of the BDNF promoter IV by Sirt1 whereas deacetylase-deficient Sirt1 did not
have an effect (Fig. 3a). While CREB alone also activated the promoter by about 2 fold,
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ttransfection of Sirt1 and CREB together resulted in synergistic 15-fold activation.
Expression of DNA binding-incompetent form of CREB (K-CREB) did not lead to
synergistic activation with Sirt1, suggesting that DNA binding of CREB is required for the
synergism (Fig. 3a). Moreover, a mutant form of CREB that cannot get phosphorylated at
Ser-133 still synergized with Sirt1, indicating that phosphorylation of CREB was not
required for the synergism. A conserved family of coactivators designated Transducers of
Regulated CREB activity (TORCs) were identified as enhancers of CREB transcription via
phosphorylation-independent interaction with CREB 3. We found that activation of BDNF
promoter by CREB was enhanced by co-transfection of TORC1 in a dose-dependent manner
(Supplementary Fig. 6a). This effect of TORC1 was dramatically potentiated by Sirt1
(Supplementary Fig. 6a) suggesting that Sirt1 activates BDNF promoter by enhancing
CREB-TORC1 transcriptional activity.
To determine how Sirt1 potentiates CREB-TORC1 activity, we next tested whether Sirt1
interacts with these factors. Previous studies suggested that TORC1 activated CREB-
regulated transcription by promoting recruitment of transcriptional coactivator TAF4 3. Here
we demonstrate that Sirt1 interacts with CREB, TORC1 and TAF4 (Fig. 3b and
Supplementary Fig. 6b) and that expression of Sirt1 potentiated the interaction of CREB
with TORC1 (Fig. 3c). Importantly, we found that Sirt1 increased the proportion of slower
migrating TORC1 (upper band in Fig. 3c), which is the form of TORC1 that predominantly
interacts with CREB.
Since Sirt1 is a deacetylase, we next examined whether it potentiates TORC1-CREB
interaction by deacetylating TORC1. Using antibody to pan-acetyl lysine, strong acetylation
of TORC1 was detected by CBP but not by catalytically inactive CBP-DY16 (Fig. 3d).
Importantly, Sirt1, but not the deacetylase-deficient Sirt1 HY was able to deacetylate
TORC1 (Fig. 3d, lower panel). Using mass spec analysis we identified acetylation of several
lysine residues in the TORC1 protein (Supplementary Fig. 7), including lysines 13, 20, 33,
178 and 197. To study the functional consequences of lysine modifications, these residues
were mutated, either individually or in various combinations, into arginine (KR) to mimic
deacetylation, or glutamine (KQ) to mimic acetylation. While no obvious effect was seen
with mutations of lysines 33, 178 and 197, the mutations of lysines 13 or 20 into KR and
KQ stabilized and destabilized TORC1, respectively (Fig. 3e). The effect of lysines 13 and
20 was most notable on the slower-migrating form of TORC1 that interacts with CREB,
suggesting that the acetylation or deacetylation status of Lys13 and to a lesser degree Lys20
plays a key role in interactions of TORC1with CREB. Since lysines 13 and 20 reside in the
TORC1 tetramerization and CREB-binding domain3, we hypothesized that these lysines
mediate the effect of Sirt1 on TORC1-CREB interaction and activation of BDNF promoter.
While wild-type or KR mutants of TORC1 potentiated CREB-mediated BDNF reporter
activity, the KQ mutations at lysines 13 or 20 exhibited significantly reduced potentiation
(Supplementary Fig. 8). These results further support the notion that deacetylation of
TORC1 by Sirt1 plays a role in activation of BDNF transcription.
As we evaluated TORC1 acetylation, it was noted that Sirt1 gave rise to an increase in
TORC1 electrophoretic mobility, the effect that was most pronounced when TORC1 was
acetylated by CBP (Fig. 3d,f, upper right panel, input). Treatment of TORC1 by alkaline
phosphatase revealed that the faster electrophoretic mobility forms of TORC1 generated by
Sirt1 expression represented dephosphorylated TORC1 (Fig. 3f, left panel). Previous studies
showed that cytoplasmic TORC1 is phosphorylated at serine 151 and inactive, whereas its
dephosphorylation leads to its nuclear translocation and activation 17,18. Using primary
neurons we confirmed that the faster-migrating dephospho TORC1 represents the nuclear
form of TORC1 (Supplementary Fig. 9a). Using specific antibody to phospho Ser151
(Supplementary Fig. 9b), we found that levels of phosphorylated TORC1 were greatly
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tdiminished in the presence of wild-type Sirt1, but not deacetylase-deficient Sirt1, further
suggesting that Sirt1 promotes the formation of dephosphorylated, active nuclear TORC1
(Fig. 3f, lower right panel). In agreement with this conclusion, we found that knockdown of
endogenous Sirt1 led to increased phosphorylation of TORC1 in primary neurons treated
with forskolin19 (Fig. 3g). Interestingly, we did not observe any changes in levels of total or
phospho CREB in the presence of Sirt1 knockdown (Supplementary Fig. 10), suggesting
that Sirt1 does not regulate CREB directly but rather via TORC1.
Together our data so far suggest that as part of its physiological function Sirt1 deacetylates
and activates neuronal TORC1. To determine if mutant HTT interferes with this normal
Sirt1 function, we first examined the localization of TORC1 in primary neurons expressing
mutant or wild-type HTT. Interestingly, expression of mutant HTT resulted in
predominantly cytoplasmic localization of TORC1, suggesting that TORC1 primarily exists
in its inactive, phosphorylated form in the presence of mutant HTT (Fig. 4a). To substantiate
this conclusion in vivo, chromatin immunoprecipitations (ChIP) revealed significantly
decreased recruitment of TORC1 to BDNF promoter IV in the cortex of R6/2 mice (Fig. 4b),
further suggesting that mutant HTT interferes with TORC1 nuclear localization and
transcriptional activity. Moreover, we found that mutant HTT interacts with Sirt1, TORC1
(Figs. 4c and Supplementary Fig. 11b,c,e,f), TAF4 (Supplementary Fig. 11a,d)20 and it
interferes with TORC1-CREB interaction (Supplementary Fig. 12a,b). Consistent with Fig.
4a, increased phosphorylation of TORC1 was noted in the presence of mutant HTT
(Supplementary Fig. 12a), suggesting that mutant HTT, possibly through its interaction with
Sirt1, interferes with the ability of Sirt1 to activate TORC1. Since TORC1 promotes
interaction of CREB with TAF4 3, and the fact that TAF4 has been previously implicated in
CREB transcription in HD20, it is also possible that interference of mutant HTT with TAF4
function contributes to transcriptional repression of BDNF gene in HD.
Since Sirt1 protected from mutant HTT toxicity and promoted the interaction of TORC1
with CREB, we examined whether expression of Sirt1 could overcome the interference of
mutant HTT. As shown in Supplementary Fig. 12b, expression of Sirt1 strongly enhanced
TORC1-CREB interaction in the presence of mutant HTT. Based on this finding and our in
vivo data showing rescue of BDNF expression by Sirt1 (Fig. 2c), we examined whether
mutant HTT and Sirt1 directly affect the BDNF promoter. Previous studies demonstrated
that wild-type HTT upregulates transcription of the BDNF gene by sequestrating the neuron-
restrictive silencing factor (NRSF) in the cytoplasm, suggesting that wild-type HTT function
plays an important protective role in the pathogenesis of HD 14,21. While those studies
examined BDNF promoter II that contains NRSF binding site, our study examined promoter
IV that is regulated by the CREB-mediated mechanism15. We found that mutant HTT, but
not the WT HTT interfered with Sirt1-mediated activation of BDNF promoter
(Supplementary Fig. 12c). Importantly, expression of Sirt1 resulted in significant reversal of
mutant HTT-mediated repression (Fig. 4d), further suggesting that Sirt1 can rescue the
effect of mutant HTT on BDNF transcription.
In light of our combined results suggesting that TORC1 plays an important role in Sirt1-
mediated protection from mutant HTT toxicity, we directly examined if Sirt1 protection
depends on the presence of TORC1. To this end, primary cortical neurons were transduced
with lentivirally-expressed mutant HTT and Sirt1 in the presence or absence of TORC1
knockdown. Using lentiviral shRNA approach, about 70% knockdown of TORC1 was
achieved that was not neurotoxic by itself (Supplementary Fig. 13a,b). Importantly, Sirt1
rescue of mutant HTT toxicity was significantly compromised in the presence of TORC1
knockdown (Fig. 4e), suggesting that expression of TORC1 is at least in part required for
Sirt1-mediated neuroprotection. Finally, we hypothesized that if Sirt1 primarily protects
from mutant HTT toxicity by activating TORC1 and consequently CREB, the knockdown of
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non-toxic knockdown of CREB at baseline, we found that Sirt1-mediated rescue of mutant
HTT toxicity was completely dependent on the presence of endogenous CREB (Fig. 4f and
Supplementary Fig. 13c). These results strengthen the conclusion that TORC1-CREB
pathway plays a critical role in mediating Sirt1 neuroprotection in neurons expressing
mutant HTT.
In sum, we demonstrate that Sirt1 plays an important neuroprotective role in the
pathogenesis of HD. Using primary neurons, we confirmed that Sirt1 directly targets
neurons to mediate neuroprotection from mutant HTT. Our data demonstrate that under
normal conditions Sirt1 promotes deacetylation of TORC1 and its interaction with CREB
which leads to activation of target genes such as BDNF. Mutant HTT interacts with Sirt1
and interferes with Sirt1-mediated activation of TORC1 that in turn results in transcriptional
repression. Importantly, overexpression of Sirt1 rescued this effect of mutant HTT in vitro
and in vivo.
Our finding that Sirt1 affords neuroprotection in R6/2 mice is in agreement with the
accompanying manuscript where Sirt1-mediated neuroprotection was observed in another
fragment model (171aa) and in full-length HD mouse model (Jiang et al.). Interestingly,
Sirt1 overexpression did not affect survival or aggregation in 171aa mice despite the
observed neuroprotection. Although the reasons for these discrepancies remain unknown, it
is important to note that 171aa mice develop hyperinsulinemia and insulin resistance that
was not seen in our model. Several published reports implicate insulin signaling in the
regulation of aggregation and proteotoxicity, but its role in neurodegeneration remains
controversial22. It is therefore possible that hyperinsulinemia in 171aa mice contributes to
differences in survival and aggregation upon Sirt1 rescue. Although it is not precisely
known why HD-like mice die, recent work23 showed that HTT fragment models (R6/2 and
171aa) develop profound hypothermia that presumably contributes to death in these animals.
Since hypothermia does not seem to play a similar role in HD patients, it can be therefore
argued that survival as outcome measure in HD-like mice may not directly inform about
human disease. However, it is generally accepted that striatal and neuronal atrophy observed
in HD-like mice strongly resemble human disease, and on this key measure, our studies are
in agreement.
We identified TORC1 as a novel target of Sirt1 deacetylase, whereas Jiang et al. showed that
previously known substrates of Sirt1 such as FoxO3a and p53 were also altered in HD
models. Since mutant HTT partially inhibits Sirt1 deacetylase activity (Jiang et al.), it is not
surprising that multiple substrates of Sirt1 exhibited increased acetylation in HD models.
Importantly, overexpression of Sirt1 was able to overcome this inhibition and partially
correct the acetylation status of Sirt1 substrates. In light of our data that TORC1 is required
for Sirt1-mediated rescue, it will be of interest to further examine possible links between
TORC1 and other Sirt1 substrates in HD. As a regulator of neuronal activity-dependent
CREB transcription, TORC1 presumably regulates other CRE-regulated genes that have
been implicated in the pathogenesis of HD. For example, recent studies suggest that TORC1
activates transcription of PGC-1alpha24, a master regulator of mitochondrial function that
has been implicated in the pathogenesis of HD23,25 and other neurodegenerative
disorders26–29. In support of this notion, we found that Sirt1 significantly rescued expression
of PGC-1alpha in R6/2 mice (Supplementary Fig. 14). The regulatory regions of FoxO3
genes contain CRE sites30 suggesting that TORC1 may also regulate FoxO3a expression. It
will be therefore of interest to examine whether Sirt1 deacetylation of TORC1 leads to
activation of multiple target genes and as such represents an upstream target of Sirt1 in
CNS. Since TORC1 is essentially brain-specific18, it represents an exciting candidate to
monitor the function of Sirt1 in neurons, especially in the context of therapeutic
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tinterventions. Together, our results suggest that pharmacological targeting of Sirt1 provides
an opportunity for therapeutic development in HD.
ONLINE METHODS
Mouse Studies
To generate BSKO-R6/2 mice, Sirt1flox/flox-nestin-cre and R6/2 were intercrossed for two
generations. Nestin-cre was always passed through the male germline. The crosses were all
carried out on a C57BL/6 background. R6/2 mice on the C57BL6/J background were
obtained from Psychogenics, Inc. Sirt1-KI-R6/2 mice were generated by intercrossing mice
heterozygous for the Sirt1-KI transgene, maintained on an outbred background 9 with R6/2
mice on the B6CBAF1/J background (Jackson Laboratories). Rotarod analysis was
performed using a Rotamex-5 Rota Rod apparatus (Columbus Instruments). For
neuropathological analyses, brain sections were examined stereologically as described 25.
The dissector counting method was used to assess striatal neurons and HTT-positive
aggregates using an unbiased random selection of serial sections in a defined volume of the
neostriatum, as described 8.
Quantitative PCR
qPCR was performed using iQ SYBR Green Supermix (Bio-Rad Laboratories) on a Light
Cycler 480 II (Roche). Primers used were: BDNF-F: 5'-
TCATACTTCGGTTGCATGAAGG-3' BDNF-R: 5'-AGACCTCTCGAACCTGCCC-3'
18S-F: 18S-R: as obtained from the Harvard Primer Bank 31. Relative mRNA abundance
was calculated using the ΔΔCT method.
Plasmids and Antibodies
Lentiviral transfer vectors HTTEx1-25Q, HTTEx1-72Q and Sirt1, BDNF-luciferase
construct (pIII(170)Luc)15, Sirt1 and Sirt1 HY plasmids, Flag- CREB, TORC1, Flag-
TORC1 and Flag-TORC1 S151A3 were described previously. CREB, K-CREB, CREB-133
and pEGFP were purchased from Clontech. Human HTTEx1 25Q-GFP, HTTEx1-103Q-
GFP, HTT480-17stop, HTT480-68stop, HA-TAF and CBP-HAT constructs were described
previously 16. Short hairpin RNA lentiviral plasmids (pLKO.1) targeting Sirt1 (5'-
AAGTTGACCTCCTCATTGTTA-3') and TORC1 (5'-
TTGATTCAGACCATCAGTTTC-3') were purchased from Sigma. Lentiviral Sirt1 HY was
generated by mutating 363 Histidine to Tyrosine. Primary antibodies to listed next were
from the following sources: neurofilament (2H3, Developmental Studies Hybridoma Bank),
Flag (F7425, Sigma), Flag M2 (F3165, Sigma), HA (HA.11, Covance, #3724, Cell
Signaling), TORC1 (#2587, Cell Signaling Technology, #6937 from M. Montminy),
phospho S151 TORC1 (#3359, Cell Signaling Technology), Myc (#2276, Cell Signaling
Technology, sc-789, Santa Cruz, MCA1929, serotec), acetyl lysine (ICP0380,
Immunechem), Sirt1 (07-131, Upstate, sc-15404, Santa Cruz, #2028, Cell Signaling and
custom-made Sirt1 antibody from L. Guarente), β-tubulin (T4026, Sigma), β3-tubulin
(#4466, Cell Signaling Technology) and HTT (MAB5492 and MAB2166, Millipore and
Ab1 from M. Difiglia).
Primary neurons
Rat and mouse embryonic primary cortical neurons prepared from E19 and E17 embryos,
respectively, were infected with lentiviral vectors at moi of 3 on DIV4. Lentivirus was
produced as previously described 32. Neurons fixed and double stained with anti-
neurofilament antibody and Draq5 + Sapphire700 were analyzed using Odyssey Infrared
Imaging System (LI-COR). Sirt1 KO and WT cultures were prepared by dissecting and
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tplating each embryo separately from E16 littermates. BDNF was added to Sirt1 KO culture
at 50 ng ml−1 every other day starting DIV5. For knockdown of Sirt1, neurons were infected
with sh scrambled or sh Sirt1 lentivirus at moi of 1 on DIV8. At 5 d post infection (DIV13),
neurons were treated with 25 µM forskolin (FSK).
Reporter assays and coimmunoprecipitations
Neuro2a (N2a) cells cultured in DMEM with 10% FBS were transfected using
Lipofectamine 2,000. Tranfected cell were harvested at 24 h post transfection unless
otherwise specified. For coimmunoprecipitation, transfected Neuro2a cells were harvested at
24 h posttransfection and coimmunoprecipitation performed as previously described 33. For
luciferase reporter assays, 50 ng of reporter was used per well of 24-well plates. Cell
extracts were prepared at 24 to 48 h posttransfection and luciferase assay performed by
standard protocol. For alkaline phosphatase treatment, Neuro2a cells co-transfected with
Flag-CREB and TORC1 was immunoprecipitated with anti-Flag antibody.
Dephosphorylation reactions were carried out on coimmunoprecipitated TORC1-containing
protein G beads.
Multidimensional Protein Identification Technology (MudPIT) and LTQ Orbitrap Mass
Spectromtery is described in the supplement
Poor quality spectra were removed from the dataset using an automated spectral quality
assessment algorithm 34. MS/MS spectra remaining after filtering were searched with the
ProLuCID algorithm35. All searches were parallelized and performed on a Beowulf
computer cluster consisting of 100 1.2GHz Athlon CPUs 36. ProLuCID 37 results were
assembled and filtered using the DTASelect (version 2.0) program 38. Confidence for
modifications was estimated from overlapping modified peptides as described previously39.
The validity of peptide/spectrum matches was assessed using the SEQUEST-defined
parameters, cross-correlation score (XCorr), and normalized difference in cross-correlation
scores (DeltaCn).
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assay from mouse brains was performed using
Magna ChIP kit (Millipore) according to manufacturer’s protocol by using TORC1 antibody
(#6937, PBL-Salk Institute) and normal rabbit IgG (Santa Cruz). The primer sequences for
BDNF promoter IV were published previously40.
Site-directed mutagenesis of TORC1
TORC1 mutants were generated by using QuikChange II XL site-directed mutagenesis kit
(Agilent). Incorporation of mutations was verified by DNA sequencing (MGH DNA
sequencing core).
Additional methods
Detailed methodology is described in the Supplementary Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Ablation of neuronal Sirt1 exacerbates and over-expression of Sirt1 ameliorates
phenotypes in R6/2 mouse
(a) Latency to fall from accelerating rotarod at 10 weeks of age. n = 4 - 10 per group. *P <
0.05 for HD vs. BSKO-HD by ANOVA. (b) Striatal volumes at 20 weeks of age. n = 4 per
group. *P < 0.01 by ANOVA. (c) Striatal neuronal volumes at 20 weeks of age. n = 4 per
group. * P < 0.05 by t-test. (d) Aggregates of HTT in striata at 20 weeks of age. ** P < 0.01
(n=6 per group) (e) Survival of male HD (closed square) and Sirt1-KI-HD (open square)
mice. n = 26 - 27 per group. P < 0.001 by log-rank test. (f) Striatal volume at 100 d of age. n
= 5 – 6 per group. * P < 0.05 by ANOVA. (g) Striatal neuronal volumes at 100 d of age. n =
5 - 6 per group. *P < 0.05 by t-test. (h) Aggregates of HTT in striata at 100 d of age. ** P <
0.01 (n=7 per group).
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tFigure 2. Deaceylase activity of Sirt1 protects cortical neurons from mutant HTT Toxicity
(a) Upper panels: neurofilament (NF) staining in primary cortical neurons infected with
indicated lentivirus. Lower panels: double staining of mt HTT- and Sirt1-infected neurons.
Scale bar, 300 µm. (b) In-cell western (ICW) for NF and Draq5 + Sapphire 700 staining of
cortical neurons infected with indicated lentivirus. *** P < 0.001 for mt HTT vs. WT HTT,
*** P < 0.001 for mt HTT + Sirt1 vs. mt HTT. (c) BNDF mRNA levels in mouse cortex at
100 d of age. *P < 0.05 for HD vs Sirt1-KI-HD by ANOVA. * P < 0.05 for Sirt1-KI vs. WT
by ANOVA (n=4 per group). (d) BDNF mRNA levels in mouse cortex at 3 months of age. n
= 5 per group. *P < 0.05 by t-test. (e) Toxicity in primary cortical neurons from Sirt1 KO
mice or WT littermates. * P < 0.05 for white bars, KO vs WT; *** P < 0.001 for black bars,
KO vs WT; *** P < 0.001 for white bars, KO + BDNF vs KO; ** P < 0.01 for black bars,
KO + BDNF vs KO by t-test.
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tFigure 3. Sirt1 deacetylates and activates TORC1
(a) BDNF promoter IV activity in N2a cells cotransfected with indicated plasmids at 24 h
posttransfection. ** P < 0.01 vs. vector + pEGFP, ***P < 0.001 vs. vector + pEGFP by t-
test. (b, c) Coimmunoprecipitations in N2a cells with indicated plasmids. (d) TORC1
immunoprecipitation and acetylation in N2a cells assessed by antibody to acetyl-lysine
(AcK) (bottom panel). Western blots of TORC1 in input samples (top panel) and IP samples
(middle panel). (e) Western blot of TORC1 KR or KQ mutants in N2a cells transfected with
indicated TORC1 mutants. Long and short exposures are shown. (f) Left: western blot of
TORC1 with or without in vitro treatment of alkaline phosphatase (APase). Right: Western
blot of TORC1 and p-TORC1 and coimmunoprecipitation assay of CREB and TORC1 in
N2a cells transfected with indicated plasmids. TORC1 position marked by arrows. (g)
Dephosphorylation of p-TORC1 by forskolin (FSK) in the presence of Sirt1 knockdown in
primary cortical neurons. Phospho-TORC1 marked with arrow heads. * P < 0.05 by t-test.
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tFigure 4. Sirt1 rescues mutant HTT-mediated interference with TORC1 activity
(a) Immunostaining of HTT, TORC1 and DAPI in primary neurons infected with lentiviral
WT HTT (upper panels) or mt HTT (lower panels). *** P < 0.001 by t-test. Scale bar, 50
µm. (b) Chromatin immunoprecipitation (ChIP) of TORC1 on BDNF in cortex of WT or
HD mice. **P < 0.01 vs WT, n = 6. (c) Coimmunoprecipitations assay of indicated plasmids
in N2a cells. (d) BDNF promoter IV activities in N2a cells cotransfected with indicated
plasmids at 48 hooo posttransfection. ** P < 0.01. (e) NF staining intensity in primary
cortical neurons infected with indicated lentivirus. * P < 0.05 by t-test. *** P < 0.001 by t-
test. (f) Toxicity was assessed as in (e). * P < 0.05, *** P < 0.001 by t-test.
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